Home > Publications Database > The prodromal individuals' perspective on active recruitment for early detection of α-synucleinopathies. > print

001     278567
005     20250601001317.0
024 7 _ |a 10.1038/s41531-025-00979-0
|2 doi
024 7 _ |a pmid:40346062
|2 pmid
024 7 _ |a pmc:PMC12064827
|2 pmc
024 7 _ |a altmetric:177026103
|2 altmetric
037 _ _ |a DZNE-2025-00600
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Röttgen, Sinah
|0 0000-0002-7553-2111
|b 0
245 _ _ |a The prodromal individuals' perspective on active recruitment for early detection of α-synucleinopathies.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1748427554_4359
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Only the timely detection of individuals with incipient α-synucleinopathies can pave the way for developing disease-modifying therapies. Our aim was to explore the views of individuals with isolated REM sleep behavior disorder (iRBD), actively recruited from the general population, on the ethical justifiability of active recruitment and their experiences with risk disclosure. This mixed-methods study surveyed individuals with iRBD, confirmed by video-polysomnography, utilizing an interdisciplinary-developed online questionnaire. Of 99 invited individuals, 75 (75.8%) answered the survey. While 55.6% experienced the information on the increased risk as burdensome, 63.9% supported risk disclosure if consent had been obtained beforehand. Almost all individuals (96.2%) regarded our active recruitment method as appropriate, and 86.7% indicated they would participate again. Open-text responses indicated that key motivations included access to information and care, and contributing to research progress. This well-received recruitment strategy could serve as a model for future screening initiatives in α-synucleinopathy research.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
700 1 _ |a Schäffer, Eva
|0 P:(DE-2719)2811829
|b 1
700 1 _ |a Rogge, Annette
|0 0000-0002-5989-0744
|b 2
700 1 _ |a Hartung, Ramona
|b 3
700 1 _ |a Kufer, Konstantin
|0 P:(DE-2719)9003179
|b 4
|u dzne
700 1 _ |a Fink, Gereon R
|0 0000-0002-8230-1856
|b 5
700 1 _ |a Berg, Daniela
|0 P:(DE-2719)2000059
|b 6
700 1 _ |a Ophey, Anja
|0 0000-0001-5858-7762
|b 7
700 1 _ |a Sommerauer, Michael
|0 P:(DE-2719)9003277
|b 8
|e Last author
|u dzne
773 _ _ |a 10.1038/s41531-025-00979-0
|g Vol. 11, no. 1, p. 121
|0 PERI:(DE-600)2819218-7
|n 1
|p 121
|t npj Parkinson's Disease
|v 11
|y 2025
|x 2373-8057
856 4 _ |u https://pub.dzne.de/record/278567/files/DZNE-2025-00600%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/278567/files/DZNE-2025-00600.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/278567/files/DZNE-2025-00600%20SUP.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/278567/files/DZNE-2025-00600.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:278567
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9003179
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)9003277
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:43:48Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:43:48Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:43:48Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NPJ PARKINSONS DIS : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
920 1 _ |0 I:(DE-2719)1013020
|k AG Petzold
|l Vascular Neurology
|x 0
920 1 _ |0 I:(DE-2719)1011302
|k AG Wüllner
|l Biomarker Parkinson's Disease
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1013020
980 _ _ |a I:(DE-2719)1011302
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21